Holistic Solutions to Schizophrenia Management in Geriatric Populations

Tatum R Dam Dam, Cassandra J Liew, Ria Soni, Anjali Mangla, Medha Illindala, K. Bs, Ank A. Agarwal, B. Baccouche, Shravika Lam, A. Bhamidipati, B. Mangla
{"title":"Holistic Solutions to Schizophrenia Management in Geriatric Populations","authors":"Tatum R Dam Dam, Cassandra J Liew, Ria Soni, Anjali Mangla, Medha Illindala, K. Bs, Ank A. Agarwal, B. Baccouche, Shravika Lam, A. Bhamidipati, B. Mangla","doi":"10.47363/jnrrr/2021(3)137","DOIUrl":null,"url":null,"abstract":"Schizophrenia is a psychiatric condition characterized by dysfunction in thoughts, behavior, and emotions. The illness is typically diagnosed in late adolescence to early adulthood, and generally lasts throughout a patient’s lifetime. This debilitating condition affects approximately 25% of adults aged 55 years old and older. With numbers of elderly adults afflicted by psychiatric illnesses increasing in the future, special precautions need to be taken to address this underserved population. This increase in schizophrenia frequency among elderly populations also has repercussions not just for future healthcare, but health costs as well, with schizophrenia expenses being costly in comparison to other psychiatric ailments. A major theory explaining the genetic and physiological basis of schizophrenia is the dopamine hypothesis, which describes a disruption in the normal transmission of the dopaminergic pathway as well as the mesolimbic system. Current treatments of schizophrenia often involve pharmacological interventions that create heightened side effects in the elderly. There is a need for more research into efficient and effective treatments for the future, especially treatments that can be safe for elderly use such as brain stimulating interventions. Destigmatizing mental health issues and advocating for safer and more efficient therapies are the key to improving outcomes of geriatric schizophrenic patients","PeriodicalId":73862,"journal":{"name":"Journal of neurology research, reviews & reports","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of neurology research, reviews & reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47363/jnrrr/2021(3)137","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Schizophrenia is a psychiatric condition characterized by dysfunction in thoughts, behavior, and emotions. The illness is typically diagnosed in late adolescence to early adulthood, and generally lasts throughout a patient’s lifetime. This debilitating condition affects approximately 25% of adults aged 55 years old and older. With numbers of elderly adults afflicted by psychiatric illnesses increasing in the future, special precautions need to be taken to address this underserved population. This increase in schizophrenia frequency among elderly populations also has repercussions not just for future healthcare, but health costs as well, with schizophrenia expenses being costly in comparison to other psychiatric ailments. A major theory explaining the genetic and physiological basis of schizophrenia is the dopamine hypothesis, which describes a disruption in the normal transmission of the dopaminergic pathway as well as the mesolimbic system. Current treatments of schizophrenia often involve pharmacological interventions that create heightened side effects in the elderly. There is a need for more research into efficient and effective treatments for the future, especially treatments that can be safe for elderly use such as brain stimulating interventions. Destigmatizing mental health issues and advocating for safer and more efficient therapies are the key to improving outcomes of geriatric schizophrenic patients
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
老年人群精神分裂症管理的整体解决方案
精神分裂症是一种以思想、行为和情感功能障碍为特征的精神疾病。这种疾病通常在青春期晚期到成年早期被诊断出来,通常会持续一生。大约25%的55岁及以上的成年人患有这种使人衰弱的疾病。随着未来受精神疾病折磨的老年人数量的增加,需要采取特别的预防措施来解决这一服务不足的人群。老年人群中精神分裂症频率的增加不仅对未来的医疗保健有影响,而且对医疗费用也有影响,与其他精神疾病相比,精神分裂症的费用要高得多。解释精神分裂症遗传和生理基础的一个主要理论是多巴胺假说,该假说描述了多巴胺能通路和中脑边缘系统正常传递的中断。目前的精神分裂症治疗通常涉及药物干预,这对老年人产生了更大的副作用。有必要对未来的高效和有效的治疗方法进行更多的研究,特别是对老年人安全使用的治疗方法,如大脑刺激干预。消除心理健康问题的污名化,倡导更安全、更有效的治疗方法,是改善老年精神分裂症患者预后的关键
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Hyperbaric Oxygen and Outcomes Following the Brain Injury: A Systematic Review. Satisfaction Rates on Telemedicine Consultations among Neurology Patients Seen at A Tertiary Hospital: A Cross- Sectional Study Impact of Post Pandemic on Environmental World Disorder Efficacy of TMS and Cognitive Training in Mild Cognitive Impairment: A Pilot Study Search for Natural Compounds - Based Therapeutic Approach against Alzheimer’s disease: Chitin and Chitosan – The Choice
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1